Health-related quality of life in secondary progressive multiple sclerosis

被引:33
作者
Beiske, A. G. [1 ]
Naess, H.
Aarseth, J. H.
Andersen, O.
Elovaara, I.
Farkkila, M.
Hansen, H. J.
Mellgren, S. I.
Sandberg-Wollheim, M.
Sorensen, P. S.
Myhr, K. M.
机构
[1] Univ Hosp Akershus, Dept Neurol, N-1478 Lorenskog, Norway
[2] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway
[3] Univ Gothenburg, Sahlgrens Univ Hosp, Inst Clin Neurosci, Gothenburg, Sweden
[4] Tampere Univ Hosp, Dept Neurol, Neuroimmunol Unit, Tampere, Finland
[5] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland
[6] Univ Helsinki, Dept Neurol, FIN-00014 Helsinki, Finland
[7] Aarhus Univ Hosp, Aarhus Hosp, Dept Neurol, DK-8000 Aarhus, Denmark
[8] Univ Hosp N Norway, Dept Neurol, Tromso, Norway
[9] Lund Univ, Univ Hosp, Dept Neurol, S-22100 Lund, Sweden
[10] Copenhagen Univ Hosp, Rigshosp, Dept Neurol, Danish MS Res Ctr, Copenhagen, Denmark
[11] Univ Bergen, Neurol Sect, Dept Clin Med, N-5020 Bergen, Norway
关键词
fatigue; multiple sclerosis; quality of life;
D O I
10.1177/13524585070130030101
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Common disability scales in multiple sclerosis (MS) are often weighted towards physical disability. Non-motor symptoms such as depression, fatigue and pain substantially influence wellbeing in MS. Health-related quality of life (HRQoL) measures the broader impact of MS and might indicate less obvious disease burdens. We analysed HRQoL, using the Nottingham Health Profile Part I (NHP-I), among 345 secondary progressive MS (SPMS) patients participating in a randomized trial of interferon-beta 1a (IFN-beta 1a), 22 mu g subcutaneously weekly, or matching placebo. The results did not reveal any beneficial effect of IFN-beta 1a in any outcome measure. NHP-I sub- and sum scores were compared for 217 population controls and correlated with demographic and clinical disease variables. SPMS patients had lower NHP-I sum and all subscores than the controls. Patients experiencing disease progression reported worse NHP-I sum scores. Increased fatigue, Expanded Disability Status Scale (EDSS) and Arm Index scores were independently associated with reduction in several NHP-I subscores. SPMS patients had significantly lower HRQoL than controls and physical disability (EDSS and Arm Index), disease progression and fatigue strongly influenced this. MS influenced subdimensions such as pain, sleep and emotional reactions. Increased focus on optimizing symptomatic treatment and psychosocial patient care could improve patients' HRQoL.
引用
收藏
页码:386 / 392
页数:7
相关论文
共 63 条
[1]   Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis [J].
Andersen, O ;
Elovaara, I ;
Färkkilä, M ;
Hansen, HJ ;
Mellgren, SI ;
Myhr, KM ;
Sandberg-Wollheim, M ;
Sorensen, PS .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2004, 75 (05) :706-710
[2]  
Auty A, 1998, CAN J NEUROL SCI, V25, P31
[3]   Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis [J].
Barnes, D ;
Hughes, RAC ;
Morris, RW ;
WadeJones, O ;
Brown, P ;
Britton, T ;
Francis, DA ;
Perkin, GD ;
Rudge, P ;
Swash, M ;
Katifi, H ;
Farmer, S ;
Frankel, J .
LANCET, 1997, 349 (9056) :902-906
[4]   Pain and sensory complaints in multiple sclerosis [J].
Beiske, AG ;
Pedersen, ED ;
Czujko, B ;
Myhr, KM .
EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 (07) :479-482
[5]   Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change [J].
Benedict, RHB ;
Wahlig, E ;
Bakshi, R ;
Fishman, I ;
Munschauer, F ;
Zivadinov, R ;
Weinstock-Guttman, B .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 231 (1-2) :29-34
[6]   A review about the impact of multiple sclerosis on health-related quality of life [J].
Benito-León, J ;
Morales, JM ;
Rivera-Navarro, J ;
Mitchell, AJ .
DISABILITY AND REHABILITATION, 2003, 25 (23) :1291-1303
[7]   Benefit of interferon β-1a on MSFC progression in secondary progressive MS [J].
Cohen, JA ;
Cutter, GR ;
Fischer, JS ;
Goodman, AD ;
Heidenreich, FR ;
Kooijmans, MF ;
Sandrock, AW ;
Rudick, RA ;
Simon, JH ;
Simonian, NA ;
Tsao, EC ;
Whitaker, JN .
NEUROLOGY, 2002, 59 (05) :679-687
[8]   MEASURING THE FUNCTIONAL IMPACT OF FATIGUE - INITIAL VALIDATION OF THE FATIGUE IMPACT SCALE [J].
FISK, JD ;
RITVO, PG ;
ROSS, L ;
HAASE, DA ;
MARRIE, TJ ;
SCHLECH, WF .
CLINICAL INFECTIOUS DISEASES, 1994, 18 :S79-S83
[9]   Sleep disorders in multiple sclerosis [J].
Fleming, WE ;
Pollak, CP .
SEMINARS IN NEUROLOGY, 2005, 25 (01) :64-68
[10]  
Ford HL, 2001, DISABIL REHABIL, V23, P516